Jazz Pharmaceuticals JAZZ and partner PharmaMar announced that they have initiated a phase III confirmatory study — LAGOON — to evaluate Zepzelca in patients with relapsed small cell lung cancer ...
Jazz Pharmaceuticals plc JAZZ announced that it enrolled the first patient in IMforte phase III study to evaluate its cancer drug Zepzelca (lurbinectedin) with Roche’s RHHBY Tecentriq (atezolizumab), ...
Shares of Jazz Pharmaceuticals JAZZ rose nearly 21% on Monday after it announced positive top-line results from the late-stage HERIZON-GEA-01 study. This study evaluated different combination regimens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results